Literature DB >> 7553302

Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses?

D L Lamm1, A P van der Meijden, H Akaza, C Brendler, P O Hedlund, Y Mizutani, T L Ratliff, M R Robinson, T Shinka.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7553302

Source DB:  PubMed          Journal:  Int J Urol        ISSN： 0919-8172            Impact factor:   3.369


× No keyword cloud information.
  7 in total

Review 1.  Non-specific immunotherapy with bacille Calmette-Guérin (BCG).

Authors:  A P van der Meijden
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 2.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

3.  The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.

Authors:  J Kondás; L Kiss; A Határ; A Kiss; T Lukács; P Szeldeli; F Törzsök; I Bodrogi
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

Review 4.  Evolving immunotherapeutic strategies in bladder and renal cancer.

Authors:  T R L Griffiths; J K Mellon
Journal:  Postgrad Med J       Date:  2004-06       Impact factor: 2.401

5.  Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer.

Authors:  Kees Hendricksen; Antoine G van der Heijden; Erik B Cornel; Henk Vergunst; Theo M de Reijke; Erika van Boven; Geert A H J Smits; Rajiv Puri; Sigrid Gruijs; J Alfred Witjes
Journal:  World J Urol       Date:  2009-02-13       Impact factor: 4.226

6.  In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.

Authors:  V Mey; E Giovannetti; F De Braud; S Nannizzi; G Curigliano; F Verweij; O De Cobelli; S Pece; M Del Tacca; R Danesi
Journal:  Br J Cancer       Date:  2006-07-25       Impact factor: 7.640

7.  Prognostic impact of Bacillus Calmette-Guérin interruption at the time of induction and consolidation.

Authors:  M Mofarej Alhogbani; J Aude Picard; M Hakim Fassi-Fehri; J Lionel Badet; C Marc Colombel
Journal:  Urol Ann       Date:  2017 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.